Showing results (1921-1930 of 2,019) with videos related to
Sort By:
Pageof 202
NPJ Breast Cancer|August 16, 2025
Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2- metastatic breast cancer: a retrospective multi-institutional Consortium analysisLetizia Pontolillo, Andrew A Davis, Lorenzo Gerratana, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 21, 2026
Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA studyP Schmid, H-C Wang, F Lynce, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 23, 2012
Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinomaC Xue, Y Huang, P Y Huang, et al.Ebiomedicine|November 4, 2022
Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancerAndrew A Davis, Lorenzo Gerratana, Katherine Clifton, et al.Diabetologia|November 6, 2008
Anti-angiogenic factors and pre-eclampsia in type 1 diabetic womenY Yu, A J Jenkins, A J Nankervis, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2025
Circulating tumor cells dynamics after CDK4/6 inhibitor for hormone-receptor positive metastatic breast cancer: a biomarker analysis from the PACE phase II studyLorenzo Gerratana, Carolina Reduzzi, Yue Ren, et al.Clinical Breast Cancer|May 8, 2025
Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer SymposiumKomal Jhaveri, Carey K Anders, Aditya Bardia, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2012
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancerLisa A Carey, Hope S Rugo, P Kelly Marcom, et al.NPJ Breast Cancer|July 20, 2017
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trialKerin Adelson, Bhuvaneswari Ramaswamy, Joseph A Sparano, et al.British Journal of Cancer|March 17, 2023
Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinomaLucy X Ma, Yifan Wang, Osvaldo Espin-Garcia, et al.Pageof 202